Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure

Eva Bartha, Izabella Solti, Aliz Szabo, Gabor Olah, Klara Magyar, Eszter Szabados, Tamas Kalai, Kalman Hideg, Kalman Toth, Domokos Gero, Csaba Szabo, Balazs Sumegi, Robert Halmosi

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Cardiomyopathy is one of the most severe side effects of the chemotherapeutic agent doxorubicin (DOX). The formation of reactive oxygen species plays a critical role in the development of cardiomyopathies, and the pathophysiological cascade activates nuclear enzyme poly(ADP-ribose) polymerase (PARP), and kinase pathways. We characterized the effects of the PARP-inhibitor and kinase-modulator compound L-2286 in DOX-induced cardiac injury models. We studied the effect of the established superoxide dismutase-mimic Tempol and compared the effects of this agent with those of the PARP inhibitor. In the rat H9C2 cardiomyocytes, in which DOX-induced poly(ADP-ribosyl)ation, L-2286 protected them from the DOX-induced injury in a concentration-dependent manner. In the in vivo studies, mice were pretreated (for 1 week) with L-2286 or Tempol before the DOX treatment. Both the agents improved the activation of cytoprotective kinases, Akt, phospho-specific protein kinase C ε, ζ/λ and suppressed the activity of cell death promoting kinases glycogen synthase kinase-3β, JNK, and p38 mitogen-activated protein kinase, but the effect of PARP inhibitor was more pronounced and improved the survival as well. L-2286 activated the phosphorylation of proapoptotic transcription factor FKHR1 and promoted the expression of Hsp72 and Hsp90. These data suggest that the mode of the cytoprotective action of the PARP inhibitor may include the modulation of kinase pathways and heat shock protein expression.

Original languageEnglish (US)
Pages (from-to)380-391
Number of pages12
JournalJournal of Cardiovascular Pharmacology
Volume58
Issue number4
DOIs
StatePublished - Oct 2011

Fingerprint

2-((2-piperidin-1-ylethyl)thio)quinazolin-4(3H)-one
Poly(ADP-ribose) Polymerases
Heat-Shock Proteins
Doxorubicin
Phosphotransferases
Heart Failure
Cardiomyopathies
ATP Synthetase Complexes
Glycogen Synthase Kinase 3
JNK Mitogen-Activated Protein Kinases
Wounds and Injuries
p38 Mitogen-Activated Protein Kinases
Cardiac Myocytes
Adenosine Diphosphate
Protein Kinase C
Superoxide Dismutase
Reactive Oxygen Species
Cell Death
Transcription Factors
Phosphorylation

Keywords

  • cardiomyopathy
  • doxorubicin
  • echocardiography
  • intracellular signaling

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure. / Bartha, Eva; Solti, Izabella; Szabo, Aliz; Olah, Gabor; Magyar, Klara; Szabados, Eszter; Kalai, Tamas; Hideg, Kalman; Toth, Kalman; Gero, Domokos; Szabo, Csaba; Sumegi, Balazs; Halmosi, Robert.

In: Journal of Cardiovascular Pharmacology, Vol. 58, No. 4, 10.2011, p. 380-391.

Research output: Contribution to journalArticle

Bartha, E, Solti, I, Szabo, A, Olah, G, Magyar, K, Szabados, E, Kalai, T, Hideg, K, Toth, K, Gero, D, Szabo, C, Sumegi, B & Halmosi, R 2011, 'Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure', Journal of Cardiovascular Pharmacology, vol. 58, no. 4, pp. 380-391. https://doi.org/10.1097/FJC.0b013e318225c21e
Bartha, Eva ; Solti, Izabella ; Szabo, Aliz ; Olah, Gabor ; Magyar, Klara ; Szabados, Eszter ; Kalai, Tamas ; Hideg, Kalman ; Toth, Kalman ; Gero, Domokos ; Szabo, Csaba ; Sumegi, Balazs ; Halmosi, Robert. / Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure. In: Journal of Cardiovascular Pharmacology. 2011 ; Vol. 58, No. 4. pp. 380-391.
@article{cfaf3acc788442c7b4b80b62a244dc10,
title = "Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure",
abstract = "Cardiomyopathy is one of the most severe side effects of the chemotherapeutic agent doxorubicin (DOX). The formation of reactive oxygen species plays a critical role in the development of cardiomyopathies, and the pathophysiological cascade activates nuclear enzyme poly(ADP-ribose) polymerase (PARP), and kinase pathways. We characterized the effects of the PARP-inhibitor and kinase-modulator compound L-2286 in DOX-induced cardiac injury models. We studied the effect of the established superoxide dismutase-mimic Tempol and compared the effects of this agent with those of the PARP inhibitor. In the rat H9C2 cardiomyocytes, in which DOX-induced poly(ADP-ribosyl)ation, L-2286 protected them from the DOX-induced injury in a concentration-dependent manner. In the in vivo studies, mice were pretreated (for 1 week) with L-2286 or Tempol before the DOX treatment. Both the agents improved the activation of cytoprotective kinases, Akt, phospho-specific protein kinase C ε, ζ/λ and suppressed the activity of cell death promoting kinases glycogen synthase kinase-3β, JNK, and p38 mitogen-activated protein kinase, but the effect of PARP inhibitor was more pronounced and improved the survival as well. L-2286 activated the phosphorylation of proapoptotic transcription factor FKHR1 and promoted the expression of Hsp72 and Hsp90. These data suggest that the mode of the cytoprotective action of the PARP inhibitor may include the modulation of kinase pathways and heat shock protein expression.",
keywords = "cardiomyopathy, doxorubicin, echocardiography, intracellular signaling",
author = "Eva Bartha and Izabella Solti and Aliz Szabo and Gabor Olah and Klara Magyar and Eszter Szabados and Tamas Kalai and Kalman Hideg and Kalman Toth and Domokos Gero and Csaba Szabo and Balazs Sumegi and Robert Halmosi",
year = "2011",
month = "10",
doi = "10.1097/FJC.0b013e318225c21e",
language = "English (US)",
volume = "58",
pages = "380--391",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure

AU - Bartha, Eva

AU - Solti, Izabella

AU - Szabo, Aliz

AU - Olah, Gabor

AU - Magyar, Klara

AU - Szabados, Eszter

AU - Kalai, Tamas

AU - Hideg, Kalman

AU - Toth, Kalman

AU - Gero, Domokos

AU - Szabo, Csaba

AU - Sumegi, Balazs

AU - Halmosi, Robert

PY - 2011/10

Y1 - 2011/10

N2 - Cardiomyopathy is one of the most severe side effects of the chemotherapeutic agent doxorubicin (DOX). The formation of reactive oxygen species plays a critical role in the development of cardiomyopathies, and the pathophysiological cascade activates nuclear enzyme poly(ADP-ribose) polymerase (PARP), and kinase pathways. We characterized the effects of the PARP-inhibitor and kinase-modulator compound L-2286 in DOX-induced cardiac injury models. We studied the effect of the established superoxide dismutase-mimic Tempol and compared the effects of this agent with those of the PARP inhibitor. In the rat H9C2 cardiomyocytes, in which DOX-induced poly(ADP-ribosyl)ation, L-2286 protected them from the DOX-induced injury in a concentration-dependent manner. In the in vivo studies, mice were pretreated (for 1 week) with L-2286 or Tempol before the DOX treatment. Both the agents improved the activation of cytoprotective kinases, Akt, phospho-specific protein kinase C ε, ζ/λ and suppressed the activity of cell death promoting kinases glycogen synthase kinase-3β, JNK, and p38 mitogen-activated protein kinase, but the effect of PARP inhibitor was more pronounced and improved the survival as well. L-2286 activated the phosphorylation of proapoptotic transcription factor FKHR1 and promoted the expression of Hsp72 and Hsp90. These data suggest that the mode of the cytoprotective action of the PARP inhibitor may include the modulation of kinase pathways and heat shock protein expression.

AB - Cardiomyopathy is one of the most severe side effects of the chemotherapeutic agent doxorubicin (DOX). The formation of reactive oxygen species plays a critical role in the development of cardiomyopathies, and the pathophysiological cascade activates nuclear enzyme poly(ADP-ribose) polymerase (PARP), and kinase pathways. We characterized the effects of the PARP-inhibitor and kinase-modulator compound L-2286 in DOX-induced cardiac injury models. We studied the effect of the established superoxide dismutase-mimic Tempol and compared the effects of this agent with those of the PARP inhibitor. In the rat H9C2 cardiomyocytes, in which DOX-induced poly(ADP-ribosyl)ation, L-2286 protected them from the DOX-induced injury in a concentration-dependent manner. In the in vivo studies, mice were pretreated (for 1 week) with L-2286 or Tempol before the DOX treatment. Both the agents improved the activation of cytoprotective kinases, Akt, phospho-specific protein kinase C ε, ζ/λ and suppressed the activity of cell death promoting kinases glycogen synthase kinase-3β, JNK, and p38 mitogen-activated protein kinase, but the effect of PARP inhibitor was more pronounced and improved the survival as well. L-2286 activated the phosphorylation of proapoptotic transcription factor FKHR1 and promoted the expression of Hsp72 and Hsp90. These data suggest that the mode of the cytoprotective action of the PARP inhibitor may include the modulation of kinase pathways and heat shock protein expression.

KW - cardiomyopathy

KW - doxorubicin

KW - echocardiography

KW - intracellular signaling

UR - http://www.scopus.com/inward/record.url?scp=80053990951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053990951&partnerID=8YFLogxK

U2 - 10.1097/FJC.0b013e318225c21e

DO - 10.1097/FJC.0b013e318225c21e

M3 - Article

VL - 58

SP - 380

EP - 391

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 4

ER -